Leerink Swann Reaffirms In-Line Rating for Juno Therapeutics, Inc. (JUNO)
Juno Therapeutics, Inc. (NASDAQ:JUNO)‘s stock had its “in-line” rating reiterated by equities research analysts at Leerink Swann in a report issued on Thursday, The Fly reports. They presently have a $56.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $34.00. Leerink Swann’s target price would suggest a potential upside of 24.69% from the stock’s current price.
A number of other equities analysts also recently weighed in on the company. BTIG Research upgraded Juno Therapeutics from a “sell” rating to a “neutral” rating in a report on Monday, August 28th. Zacks Investment Research downgraded Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 28th. Wells Fargo & Company reiterated an “outperform” rating and issued a $54.00 target price (up previously from $35.00) on shares of Juno Therapeutics in a report on Tuesday, September 5th. Barclays PLC started coverage on Juno Therapeutics in a report on Wednesday, September 6th. They issued an “overweight” rating and a $55.00 target price on the stock. Finally, Vetr upgraded Juno Therapeutics from a “hold” rating to a “buy” rating and set a $28.85 target price on the stock in a report on Monday, July 17th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $43.20.
Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.07. The company had revenue of $44.80 million for the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm’s quarterly revenue was up 115.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.57) EPS.
COPYRIGHT VIOLATION WARNING: “Leerink Swann Reaffirms In-Line Rating for Juno Therapeutics, Inc. (JUNO)” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/02/leerink-swann-reaffirms-in-line-rating-for-juno-therapeutics-inc-juno.html.
In related news, EVP Robert Azelby sold 12,850 shares of the stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $44.95, for a total value of $577,607.50. Following the transaction, the executive vice president now owns 37,439 shares in the company, valued at $1,682,883.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Sunil Agarwal sold 7,285 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $44.76, for a total value of $326,076.60. The disclosure for this sale can be found here. Insiders sold 85,004 shares of company stock worth $3,551,561 in the last 90 days. 15.26% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. acquired a new position in Juno Therapeutics in the third quarter worth approximately $510,000. Aperio Group LLC increased its holdings in Juno Therapeutics by 4.2% in the third quarter. Aperio Group LLC now owns 29,554 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 1,194 shares during the last quarter. Ardsley Advisory Partners acquired a new position in Juno Therapeutics in the second quarter worth approximately $299,000. Broadfin Capital LLC increased its holdings in Juno Therapeutics by 49.2% in the second quarter. Broadfin Capital LLC now owns 262,100 shares of the biopharmaceutical company’s stock worth $7,834,000 after buying an additional 86,400 shares during the last quarter. Finally, Wasatch Advisors Inc. acquired a new position in Juno Therapeutics in the second quarter worth approximately $19,787,000. Hedge funds and other institutional investors own 67.18% of the company’s stock.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.